Kinnate Biopharma Inc. (NASDAQ:KNTE) Given Average Rating of “Hold” by Brokerages

Shares of Kinnate Biopharma Inc. (NASDAQ:KNTEGet Free Report) have been assigned a consensus recommendation of “Hold” from the five ratings firms that are covering the company, MarketBeat.com reports. Four investment analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. The average 1 year price target among brokers that have covered the stock in the last year is $12.20.

Separately, Wedbush restated a “neutral” rating and issued a $2.00 target price on shares of Kinnate Biopharma in a research note on Wednesday, January 17th.

Check Out Our Latest Report on Kinnate Biopharma

Kinnate Biopharma Trading Down 0.9 %

Shares of NASDAQ KNTE opened at $2.29 on Friday. The stock has a market capitalization of $107.88 million, a price-to-earnings ratio of -0.82 and a beta of 1.35. The firm’s 50-day moving average price is $2.37 and its 200-day moving average price is $2.05. Kinnate Biopharma has a 12-month low of $1.04 and a 12-month high of $7.41.

Kinnate Biopharma (NASDAQ:KNTEGet Free Report) last released its quarterly earnings data on Thursday, November 9th. The company reported ($0.65) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.69) by $0.04. On average, equities analysts predict that Kinnate Biopharma will post -2.5 EPS for the current fiscal year.

Hedge Funds Weigh In On Kinnate Biopharma

Several institutional investors and hedge funds have recently bought and sold shares of the company. Foresite Capital Management V LLC raised its stake in shares of Kinnate Biopharma by 78.5% in the 2nd quarter. Foresite Capital Management V LLC now owns 3,525,957 shares of the company’s stock valued at $10,684,000 after acquiring an additional 1,550,956 shares during the period. FMR LLC boosted its holdings in shares of Kinnate Biopharma by 51.9% in the 2nd quarter. FMR LLC now owns 2,193,316 shares of the company’s stock valued at $27,658,000 after buying an additional 749,012 shares in the last quarter. BML Capital Management LLC acquired a new position in shares of Kinnate Biopharma in the 4th quarter valued at $1,110,000. Citigroup Inc. boosted its stake in Kinnate Biopharma by 53,138.6% during the 3rd quarter. Citigroup Inc. now owns 420,585 shares of the company’s stock worth $589,000 after purchasing an additional 419,795 shares during the period. Finally, Acadian Asset Management LLC boosted its stake in Kinnate Biopharma by 1,389.9% during the 2nd quarter. Acadian Asset Management LLC now owns 430,802 shares of the company’s stock worth $1,304,000 after purchasing an additional 401,887 shares during the period.

Kinnate Biopharma Company Profile

(Get Free Report

Kinnate Biopharma Inc, a clinical-stage oncology company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; KIN-3248 small-molecule kinase inhibitors that target cancer-associated alterations in fibroblast growth factor receptors FGFR2 and FGFR3 genes; and small molecule research programs, including Cyclin-Dependent Kinase 12(CDK12) inhibitor in its KIN004 program.

See Also

Analyst Recommendations for Kinnate Biopharma (NASDAQ:KNTE)

Receive News & Ratings for Kinnate Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kinnate Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.